title: Chrysin restores PDGF-induced inhibition on protein tyrosine phosphatase and reduces PDGF signaling in cultured VSMCs.
abstract: Previous studies have shown that an increased intake of dietary flavonoids is associated with a decreased risk of cardiovascular diseases (CVDs). PDGF is a major mitogen for vascular smooth muscle cell (VSMC) and participates in the pathogenesis of many CVDs. The study investigated whether the flavone chrysin affected PDGF functions in VSMCs and neointma formation in rat artery. We found that chrysin concentration-dependently inhibited PDGF-induced proliferation and chemotaxis and reduced PDGF signaling in VSMCs. Chrysin attenuated H(2)O(2) signaling and PDGF-induced reactive oxygen species production and NADPH oxidase activation but did not interfere with PDGF binding to VSMCs. The further analyses revealed that chrysin relieved PDGF-induced inhibition on activity of protein tyrosine phosphatase (PTP) and reduced PDGF-induced oxidation of PTP cysteinyl active site. Moreover, it inhibited PDGF receptor autophosphorylation induced by low-dose vanadate (an inhibitor for PTP). The effect of chrysin, but not of the flavonoid (-)-epigallocatechin-3-gallate and antioxidant N-acetylcysteine, on PDGF signaling and PTP activity was reversed by depletion of intracellular glutathione (GSH), suggesting an involvement of chrysin on GSH/glutaredoxin system for PTP reactivation. Finally, to demonstrate the effectiveness of chrysin in vivo, we showed that oral administration of chrysin before and after angioplasty could reduce neointima formation in balloon-injured carotid artery in rats. In conclusion, we provide here evidence that chrysin can regulate intracellular PTP activity during PDGF signaling, inhibits PDGF-induced VSMC proliferation and chemotaxis, and reduces arterial intima hyperplasia in vivo.
authors.affiliation: School of Medicine, Fu-Jen Catholic University, Hsinchuang, Taipei 24205, Taiwan.
authors.forename: Huey-Ming
authors.initials: HM
authors.lastname: Lo
authors.forename: Min-Wen
authors.initials: MW
authors.lastname: Wu
authors.forename: Shiow-Lin
authors.initials: SL
authors.lastname: Pan
authors.forename: Chieh-Yu
authors.initials: CY
authors.lastname: Peng
authors.forename: Pi-Hui
authors.initials: PH
authors.lastname: Wu
authors.forename: Wen-Bin
authors.initials: WB
authors.lastname: Wu
mesh_terms: D000111:Acetylcysteine / Q000494:pharmacology; D000284:Administration, Oral; D000818:Animals; D000975:Antioxidants / Q000494:pharmacology; D002392:Catechin / Q000031:analogs & derivatives / Q000494:pharmacology; D049109:Cell Proliferation / Q000187:drug effects; D005419:Flavonoids / Q000494:pharmacology*; D005978:Glutathione / Q000378:metabolism; D006861:Hydrogen Peroxide / Q000378:metabolism; D006965:Hyperplasia / Q000188:drug therapy / Q000473:pathology; D009131:Muscle, Smooth, Vascular / Q000166:cytology* / Q000187:drug effects* / Q000378:metabolism; D019255:NADPH Oxidases / Q000378:metabolism; D058426:Neointima / Q000188:drug therapy / Q000473:pathology; D010766:Phosphorylation; D010982:Platelet-Derived Growth Factor / Q000235:genetics* / Q000378:metabolism; D017027:Protein Tyrosine Phosphatases / Q000037:antagonists & inhibitors* / Q000235:genetics / Q000378:metabolism; D051381:Rats; D017382:Reactive Oxygen Species / Q000378:metabolism; D017479:Receptors, Platelet-Derived Growth Factor / Q000037:antagonists & inhibitors / Q000235:genetics / Q000378:metabolism; D015398:Signal Transduction / Q000187:drug effects; D017539:Tunica Intima / Q000187:drug effects / Q000378:metabolism / Q000473:pathology; D014638:Vanadates / Q000378:metabolism
chemical_list: D000975:Antioxidants; D005419:Flavonoids; D010982:Platelet-Derived Growth Factor; D017382:Reactive Oxygen Species; C043561:chrysin; D014638:Vanadates; D002392:Catechin; D006861:Hydrogen Peroxide; C045651:epigallocatechin gallate; D019255:NADPH Oxidases; D017479:Receptors, Platelet-Derived Growth Factor; D017027:Protein Tyrosine Phosphatases; D005978:Glutathione; D000111:Acetylcysteine